Objectives

Work Package 4 has two Co-Lead Partners; LBI and ZIN

  • To produce joint health technology assessments. The joint assessments should be fit for purpose, of high quality, of timely availability, and cover the whole range of health technologies.
  • To refine the production processes of joint assessment reports based on lessons learned and experiences from Joint Action 2 and probe a stepped roll-out of additional collaborative assessments yielding timely information.
  • To develop and refine a system of horizon scanning, topic selection and prioritisation in close collaboration with the Liaison Committee and relevant Work Packages .
  • To develop a process that facilitates the implementation of the joint assessment in the national and regional practice.
  • To provide input on final processes and recommendations for a sustainable model of European collaboration on joint assessments after 2020.

Deliverables

Work Package 4 will:

  • produce joint assessments and collaborative assessments:
     18 Joint Assessments and 25 Collaborative Assessments on other technologies 
     33 Joint Assessments and 4 Collaborative Assessments on pharmaceuticals
  • deliver a refined production processes for joint assessments (relative effectiveness assessments).
  • implement a stepwise work-division towards a decentralised project management.
  • develop and refine a system for horizon scanning, topic selection and prioritisation of health technologies for relative effectiveness assessments
  • facilitate the implementation of joint assessments in national/local practice
  • provide input on recommendations for a sustainable model of European collaboration on joint assessments after 2020

Milestone

  •  Recommendations for horizon scanning, topic selection and prioritization are implemented (in collaboration with Liaison committee and Work Package 7)
  •  A process is established for facilitating implementation of joint assessments in national practice will be established in a majority of Member States. 
  • Stakeholder implementation in the joint work
  • A framework for alignment of joint single technology assessments for pharmaceuticals with EMA processes including early access to data during the assessments of the CHMP are implemented and structurally used.
  • Implement a sustainable production process of European joint assessments as part of a sustainable model for coordination of future European joint assessment collaboration after 2020.
  • Determine a sustainable number of joint single technology assessments for pharmaceuticals and joint assessments for other technologies to be completed in Joint Action 3.
  • Provide an update on status of the use of additional elements such as conclusions on added therapeutic value and (parts of) cost-effectiveness assessments, in discussion with the Executive Board, could be incorporated in assessment reports. This update may also include a clear description of an adoption process for the joint reports.

Partners

Lead Partner

NIPHNO (formerly NOKC)

The Norwegian Institute of Public Health
P.O. Box 4404 Nydalen
0403 Oslo
Norway
Telephone: +47 21 07 70 00
folkehelseinstituttet@fhi.no
 
Disclaimer: The Norwegian Knowledge Centre for the Health Services (NOKC), a founding partner, is incorporated in the Norwegian Institute of Public Health as of 1 January 2016.

 

 

Co-Lead Partner

Associated Partners